Particularly, Huang et al. analyzed the mutational profile of TP53 (c.747 G > T), CTNNB1 (c.121A > G, c.133 T > C), and TERT promoter (−124 C > T) in 48 HCC cases by digital droplet PCR assay and found that 56.3% of patients had at least one mutation in cfDNA and 22.2% had concordant mutations in tumour DNA and cfDNA [57]. This evidence concerns the gene TP53 and hepatocellular carcinoma.